Technical Analysis for RDY - Dr. Reddy's Laboratories Ltd

Grade Last Price % Change Price Change
grade A 37.22 -0.21% -0.08
RDY closed up 0.59 percent on Thursday, January 17, 2019, on 2.18 times normal volume.

Earnings due: Jan 24

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Up Up Up
See historical RDY trend table...

Date Alert Name Type % Chg
Jan 17 Crossed Above 20 DMA Bullish -0.21%
Jan 17 Pocket Pivot Bullish Swing Setup -0.21%
Jan 17 Bollinger Band Squeeze Range Contraction -0.21%
Jan 17 Outside Day Range Expansion -0.21%
Jan 17 Up 3 Days in a Row Strength -0.21%
Jan 16 20 DMA Resistance Bearish 0.38%
Jan 16 Bollinger Band Squeeze Range Contraction 0.38%
Jan 15 20 DMA Resistance Bearish 1.20%
Jan 15 Pocket Pivot Bullish Swing Setup 1.20%
Jan 15 Bollinger Band Squeeze Range Contraction 1.20%

Older signals for RDY ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Dr. Reddy's Laboratories Limited operates as an integrated pharmaceutical company. It operates in three segments: Pharmaceutical services and Active Ingredients (PSAI), Global Generics, and Proprietary Products. The PSAI segment develops active pharmaceutical ingredients (APIs) and intermediaries, which are used as principal ingredients for finished pharmaceutical products. This segment also offers contract research services to biotech and pharmaceutical companies; and manufactures and sells APIs and steroids in accordance with the specific customer requirements. The Global Generics segment produces and markets finished pharmaceutical products as branded formulations or generic finished dosages. This segment also engages in the operation of biologics business. The Proprietary Products segment engages in the discovery and development of new chemical entities for subsequent commercialization and out-licensing. It offers new, synergistic combination, and technology formulations that modifies pharmacokinetics of existing medicines. This segment is also involved in the Company's specialty pharmaceuticals business that includes sales and marketing operations for in-licensed and co-developed dermatology. The company offers its products and services primarily in the areas of gastrointestinal, cardiovascular, pain management, and oncology therapies. It primarily operates in India, the United States, Russia and other countries of the former Soviet Union, Europe, and others. Dr. Reddy's Laboratories Limited was founded in 1984 and is headquartered in Hyderabad, India.
Is RDY a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 3 bullish, 0 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 39.96
52 Week Low 28.13
Average Volume 234,641
200-Day Moving Average 33.5868
50-Day Moving Average 36.4626
20-Day Moving Average 37.0925
10-Day Moving Average 36.885
Average True Range 0.7226
ADX 9.82
+DI 24.7976
-DI 23.7171
Chandelier Exit (Long, 3 ATRs ) 35.8122
Chandelier Exit (Short, 3 ATRs ) 38.1878
Upper Bollinger Band 37.9253
Lower Bollinger Band 36.2597
Percent B (%b) 0.62
BandWidth 4.490396
MACD Line 0.0867
MACD Signal Line 0.1463
MACD Histogram -0.0596
Fundamentals Value
Market Cap 6.18 Billion
Num Shares 166 Million
EPS 1.07
Price-to-Earnings (P/E) Ratio 34.86
Price-to-Sales 2.69
Price-to-Book 3.07
PEG Ratio 0.00
Dividend 0.31
Dividend Yield 0.83%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 38.34
Resistance 3 (R3) 38.28 37.88 38.16
Resistance 2 (R2) 37.88 37.62 37.91 38.10
Resistance 1 (R1) 37.59 37.45 37.74 37.65 38.05
Pivot Point 37.19 37.19 37.26 37.22 37.19
Support 1 (S1) 36.90 36.93 37.05 36.96 36.55
Support 2 (S2) 36.50 36.76 36.53 36.50
Support 3 (S3) 36.21 36.50 36.44
Support 4 (S4) 36.27